| Clinical data | |
|---|---|
| Trade names | Ontak, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611024 |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Eliminationhalf-life | 70-80 min |
| Identifiers | |
| |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2560H4042N678O799S17 |
| Molar mass | 57647.46 g·mol−1 |
 N Y (what is this?) (verify) | |
Denileukin diftitox, sold under the brand nameOntak among others, is ananti-cancer medication used for the treatment of adults withT-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combininginterleukin-2 anddiphtheria toxin.[3]
Denileukin diftitox isindicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.[1][2]
The prescription label contains aboxed warning thatcapillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.[1][2]
In 1999, denileukin diftitox was approved by the USFood and Drug Administration (FDA) for the treatment ofcutaneous T-cell lymphoma.[1][4]
